Xenleta™ (lefamulin), developed by Nabriva Therapeutics, has been approved by the US FDA for adults with community-acquired bacterial pneumonia, marking the first new antibiotic with a novel mechanism of action to be approved in nearly two decades.
In this interview we speak to Vincent Racaniello, Professor of Microbiology & Immunology, about his work on polio, picornaviruses and publicizing science through blogs and podcasts.
The US FDA has approved Pretomanid tablets in combination with bedaquiline and linezolid for the treatment of specific types of drug-resistant pulmonary tuberculosis.
Graham Hatfull speaks about heading up the SEA-PHAGES project and the role this has played in understanding phage diversity and evolution, in addition to commenting on a recent case where a phage cocktail was used to treat a case of Mycobacterium abscessus.
A study of four Ebola therapeutics demonstrated that two drugs showed significantly improved survival rates, leading to the trial being halted early.
The first chlamydia vaccine to reach Phase I clinical trials has been observed to be safe and immunogenic in 35 women.
Researchers discover Clostridium difficile is evolving due to genetic changes that allow it to thrive on the Western diet and evade disinfectants making it highly adapted to spread in hospitals.
Coagulation factors, which normally function to clot blood, have been demonstrated to have antibacterial action against Gram-negative bacteria in vitro and in mouse models.
In a study of healthy infants, researchers discover exposure to C. difficile in infancy may provide natural immunization later in childhood.